Indolent mantle cell lymphoma

Haematologica

Volumn 96, Issue 8, 2011, Pages 1086-1088

  Furtado, Michelle ^a   Rule, Simon ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; TRANSCRIPTION FACTOR SOX4;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; DIAGNOSTIC VALUE; EDITORIAL; GENE; GENE EXPRESSION PROFILING; HUMAN; IVGH GENE; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; SOX11 GENE; SURVIVAL TIME;

BONE MARROW; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; LYMPHOCYTOSIS; LYMPHOMA, MANTLE-CELL; MALE;

EID: 79961093144     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047357     Document Type: Editorial

References (21)

1. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer (IARC); 2008.
2. Raffeld M, Jaffe ES. Bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78(2):259-63.
3. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-13.
4. Eve HE, Furtado MV, Hamon MD, Rule SAJ. Time to treatment does not influence overall survival in newly diagnosed mantle cell lymphoma. J Clin Oncol. 2009;27(32):e189-90.
5. Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-18.
6. Haslinger A, Schwartz T, Covic M, Chichung Lie D. Expression of SOX11 in adult neurogenic niches suggests a stage-specific role in adult neurogenesis. Eur J Neurosci. 2009;29(11):2103-14.
7. Ya J, Schilham MW, Boer PA de, Moorman AF, Clevers H, Lamers WH. Sox4-deficiency syndrome in mice is an animal model for common trunk. Circ Res. 1998;83(10):986-94.
8. Sock E, Rettig SD, Enderich J, Bösl MR, Tamm ER, Wegner M. Gene targeting reveals a widespread role for the high-mobility-group transcription factor Sox11 in tissue remodelling. Mol Cell Biol. 2004;24(15):6635-44.
9. Wang X, Björklund S, Wasik AM, Grandien A, Andersson P, Kimby E, et al. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma. PloS one. 2010;5(11):e14085.
10. Gustavsson E, Sernbo S, Andersson E, Brennan DJ, Dictor M, Jerkeman M, et al. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Mol Cancer. 2010;9:187.
11. Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111(2):800-5.
12. Dictor M, Ek S, Sundberg M, Warenholt J, Gyorgy C, Sernbo S, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009;94(11):1563-8.
13. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. 2008;143(2):248-52.
14. Kienle D, Kröber A, Katzenberger T, Ott G, Leupolt E, Barth TFE, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102(8):3003-9.
15. Lai R, Lefresne SV, Franko B, Hui D, Mirza I, Mansoor A, et al. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol. 2006;19(11):1498-505.
16. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-81.
17. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-97.
18. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Hoof A van, KluinNelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65.
19. Ondrejka SL, Lai R, Kumar N, Smith SD, Hsi ED. Indolent mantle cell leukemia: clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, k light chain restriction, and good prognosis. Haematologica. 2011;96(8)1221-7.
20. Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Beà S, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007;109(12):2473-80.
21. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11): 1555-62.